|
|
|
|
mRNA technology has been proven to enable rapid drug development. mRNA is an attractive modality to work with for its relative simplicity compared to other biologics; it is wholly synthetic and does not require cellular materials. We developed a cost model to compare all vaccine modalities, which enables decision-making on production scale and plant sizing. Here, we highlight several aspects of the cost-modeling work, such as the distribution of costs and cost per vaccine dose, and we propose various scenarios to meet forecasted mRNA demand.
|
|
|
|
|
In this article, we share key findings from the research MilliporeSigma conducted with the Economist Intelligence Clearstate, a division of The Economist, on the future of vaccine manufacturing in the Asia Pacific region.
|
|
|
|
|
Single-use technologies are well-suited for the manufacture of mRNA. Not only do they offer increased flexibility, but they can also be adapted to accommodate different dosages and scale-up strategies. This webinar describes the advantages of single-use and how these technologies overcome the challenges presented by conventional approaches to manufacturing.
|
|
|
|
|
Given the complexity of the mRNA modality, rigorous characterization and testing are required to ensure safe and effective mRNA drug products. This white paper provides a detailed description of assays for sequence identification and LNP composition, two critical quality attributes of mRNA-LNP products.
|
|
|
|
|
Plasmid DNA (pDNA) is an important component of mRNA, vaccines, and viral vector therapies. Scaling and optimizing downstream processes during manufacturing requires an in-depth knowledge of all unit operations. This webinar presents a design for a generic manufacturing template that overcomes the challenges associated with the purification of pDNA, i.e., high viscosity, large molecule size, shear sensitivity, and similarities with impurities.
|
|
|
|
|
|
|
